Concurrently, the CTLA4– PD1+, CTLA4+ PD1–, and CTLA4+ PD1+ subgroups exhibited a notable advantage in immunotherapy for low-risk gastric cancer (Figures 9F, E, H). This evidence concerns the gene CTLA4 and gastric cancer.